Baseline considerations it lists include an A1C above 7.5 percent, BMI, kidney function and cardiovascular disease status
Clients exploring it often want a peptide lane adjacent to GLP-1 programs always under NP supervision with honest evidence limits
No long-term animal studies have been performed to evaluate the carcinogenic potential of levocarnitine
Direct contact of essential oils with a mucous membrane is considered internal use, which requires more advanced training than is available at the Herbal Academy and should only be conducted under the supervision of a medical professional or aromatherapist trained in the internal use of essential oils
Even a 0.5% reduction in A1c is considered clinically meaningful, as it can lower the risk of heart disease and other complications of T2D, such as kidney and nerve damage, so that level of reduction particularly on top of existing recommended treatment is a win
This is where things get tricky